Cardiol Therapeutics Valuation
| CRDL Stock | USD 1.41 0.01 0.70% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Cardiol Therapeutics shows a prevailing Real Value of $1.33 per share. The current price of the firm is $1.41. Our model approximates the value of Cardiol Therapeutics from analyzing the firm fundamentals such as Return On Equity of -1.08, current valuation of 105.25 M, and Shares Owned By Insiders of 3.91 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Cardiol Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Cardiol Therapeutics is based on 3 months time horizon. Increasing Cardiol Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cardiol stock is determined by what a typical buyer is willing to pay for full or partial control of Cardiol Therapeutics Class. Since Cardiol Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cardiol Stock. However, Cardiol Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.41 | Real 1.33 | Hype 1.41 | Naive 1.49 |
The intrinsic value of Cardiol Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Cardiol Therapeutics' stock price.
Estimating the potential upside or downside of Cardiol Therapeutics Class helps investors to forecast how Cardiol stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cardiol Therapeutics more accurately as focusing exclusively on Cardiol Therapeutics' fundamentals will not take into account other important factors: Cardiol Therapeutics Total Value Analysis
Cardiol Therapeutics Class is currently forecasted to have valuation of 105.25 M with market capitalization of 116.16 M, debt of 174.34 K, and cash on hands of 70.45 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cardiol Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
105.25 M | 116.16 M | 174.34 K | 70.45 M |
Cardiol Therapeutics Asset Utilization
One of the ways to look at asset utilization of Cardiol is to check how much profit was generated for every dollar of assets it reports. Cardiol Therapeutics Class shows a negative utilization of assets of -0.54 percent, losing $0.005415 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cardiol Therapeutics Class shows how discouraging it operates for each dollar spent on its assets.Cardiol Therapeutics Ownership Allocation
Cardiol Therapeutics holds a total of 81.6 Million outstanding shares. Cardiol Therapeutics Class shows 3.91 percent of its outstanding shares held by insiders and 9.5 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cardiol Therapeutics Profitability Analysis
Net Loss for the year was (28.13 K) with profit before overhead, payroll, taxes, and interest of 78.76 K.About Cardiol Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Cardiol Therapeutics Class. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cardiol Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Cardiol Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Cardiol Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cardiol Therapeutics. We calculate exposure to Cardiol Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cardiol Therapeutics's related companies.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease . Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Cardiol Therapeutics is traded on NASDAQ Exchange in the United States.
Cardiol Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cardiol Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 64.5 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.